Thyroid cancer has become one of the fastest-growing malignancies in recent years, with a significant improvement in the 5-year relative survival rate among Chinese patients. Accurate diagnosis, standardized treatment, and effective follow-up are essential to improve clinical outcomes, while the promotion and implementation of clinical guidelines are critical for achieving standardized and homogeneous management. In 2022, the China Anti-Cancer Association (CACA) released the 2022 Chinese Guidelines for Integrated Diagnosis and Treatment of Tumors (CACA) — Thyroid Cancer, which systematically applied the concept of multidisciplinary integrated management to the entire care continuum of thyroid cancer, reflecting both Chinese characteristics and local experience. Building upon this, the 2025 edition of the guidelines was updated and revised based on the latest evidence and clinical practices. This article provides a systematic interpretation of the 2025 CACA guidelines, focusing on the diagnosis, treatment, and follow-up of thyroid cancer, with the aim of offering practical guidance for clinicians and promoting standardized, integrated management of thyroid cancer in clinical practice.